BCLT will host a panel discussion of issues of great importance to healthcare and biotechnology: the patentabilty of Diagnostic methods and DNA. The discussion will focus on the doctrinal and societal implications of two current cases:
Prometheus v Mayo and
AMP v Myriad.
In the recent Prometheus case, the US Supreme Court held that a claim that covers specific correlations between blood test results and patient health is not eligible for patent protection.
In the Myriad case, a pending petition for certiorari seeks Supreme Court review of the Federal Circuit decision overturning a summary judgment ruling that various claims to DNA lack patent-eligibility.
Janet Xiao will join the program panel. For more information,
click here.
2.0 hours of CLE will be available to attendees.